Bimekizumab reduces psoriatic arthritis symptoms

A drug called bimekizumab shows rapid, clinically meaningful improvements to patient reported outcomes in psoriatic arthritis that were sustained up to one year, according to research in Rheumatology. Improvements in physical and psychological scores were seen as early as four weeks into treatment and continued throughout the year that the patients were tracked.
“Psoriatic arthritis is a chronic, inflammatory disease that can significantly impact health-related quality of life across physical, social and emotional aspects,” highlights Prof Laure Gossec who is involved in the work.
Bimekizumab is already available on the NHS under expert supervision as a possible treatment for plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

PS Did you know that Arthritis Digest Magazine is labelled the best UK Arthritis blog from thousands of blogs on the web ranked by traffic, social media followers, domain authority & freshness?